These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35093016)

  • 1. Description of antibiotic treatment in adults tested for Clostridioides difficile infection: a single-center case-control study.
    Kim MH; Kim YC; Kim JL; Park YS; Kim H
    BMC Infect Dis; 2022 Jan; 22(1):104. PubMed ID: 35093016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates.
    Guh AY; Hatfield KM; Winston LG; Martin B; Johnston H; Brousseau G; Farley MM; Wilson L; Perlmutter R; Phipps EC; Dumyati GK; Nelson D; Hatwar T; Kainer MA; Paulick AL; Karlsson M; Gerding DN; McDonald LC
    Clin Infect Dis; 2019 Oct; 69(10):1667-1674. PubMed ID: 30615074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection.
    Xuan S; Zangwill KM; Ni W; Ma J; Hay JW
    J Gen Intern Med; 2020 Apr; 35(4):1102-1110. PubMed ID: 32016703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing a Clostridium difficile testing algorithm and its effect on isolation duration and treatment initiation: a pre- and post-implementation study.
    Vogelzang EH; Lankelma JM; van Mansfeld R; van Prehn J; van Houdt R
    Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1071-1076. PubMed ID: 31970532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.
    Kelly CP; Chen X; Williams D; Xu H; Cuddemi CA; Daugherty K; Barrett C; Miller M; Foussadier A; Lantz A; Banz A; Pollock NR
    Clin Infect Dis; 2020 Mar; 70(6):1083-1093. PubMed ID: 31211839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes and treatment necessity in patients with toxin-negative Clostridioides difficile stool samples.
    Cho DH; Kim SH; Jeon CH; Kim HT; Park KJ; Kim J; Kwak J; Kwan BS; Kong S; Lee JW; Kim KM; Wi YM
    Ann Clin Microbiol Antimicrob; 2024 Apr; 23(1):35. PubMed ID: 38664689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of laboratory tests for detection for Clostridioides difficile: A multicenter prospective study in Japan.
    Senoh M; Kato H; Honda H; Fukuda T; Tagashira Y; Horiuchi H; Chiba H; Suzuki D; Hosokawa N; Kitazono H; Norisue Y; Kume H; Mori N; Morikawa H; Kashiwagura S; Higuchi A; Kato H; Nakamura M; Ishiguro S; Morita S; Ishikawa H; Watanabe T; Kojima K; Yokomaku I; Bando T; Toimoto K; Moriya K; Kasahara K; Kitada S; Ogawa J; Saito H; Tominaga H; Shimizu Y; Masumoto F; Tadera K; Yoshida J; Kikuchi T; Yoshikawa I; Watanabe T; Honda M; Yokote K; Toyokawa T; Miyazato H; Nakama M; Mahe C; Reske K; Olsen MA; Dubberke ER
    Anaerobe; 2019 Dec; 60():102107. PubMed ID: 31647977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
    Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
    Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
    Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
    Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost of illness comparison for toxigenic Clostridioides difficile diagnosis algorithms in developing countries.
    Cançado GGL; Abreu ES; Nardelli MJ; Serwa P; Brachmann M
    Anaerobe; 2021 Aug; 70():102390. PubMed ID: 34058377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential underreporting of treated patients using a
    Guh AY; Fridkin S; Goodenough D; Winston LG; Johnston H; Basiliere E; Olson D; Wilson CD; Watkins JJ; Korhonen L; Gerding DN
    Infect Control Hosp Epidemiol; 2024 May; 45(5):590-598. PubMed ID: 38268440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients.
    Miller R; Morillas JA; Brizendine KD; Fraser TG
    J Clin Microbiol; 2020 Feb; 58(3):. PubMed ID: 31896665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.
    Humphries RM; Uslan DZ; Rubin Z
    J Clin Microbiol; 2013 Mar; 51(3):869-73. PubMed ID: 23269736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordant
    Lenggenhager L; Zanella MC; Poncet A; Kaiser L; Schrenzel J
    BMJ Open; 2020 Sep; 10(9):e036342. PubMed ID: 32928850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 2-step algorithm combining glutamate dehydrogenase and nucleic acid amplification tests for the detection of Clostridioides difficile in stool specimens.
    Liu C; Tang C; Han Y; Xu Y; Ni F; Jin K; Liu G
    Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):345-351. PubMed ID: 32944896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes.
    Yepez Guevara EA; Aitken SL; Olvera AV; Carlin L; Fernandes KE; Bhatti MM; Garey KW; Adachi J; Okhuysen PC
    Clin Infect Dis; 2021 May; 72(10):e460-e465. PubMed ID: 32803229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the introduction of nucleic acid amplification testing on Clostridioides difficile detection and ribotype distribution in Wales.
    Perry MD; White PL; Morris TE
    Anaerobe; 2021 Feb; 67():102313. PubMed ID: 33309680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay.
    Pollock NR; Banz A; Chen X; Williams D; Xu H; Cuddemi CA; Cui AX; Perrotta M; Alhassan E; Riou B; Lantz A; Miller MA; Kelly CP
    Clin Infect Dis; 2019 Jan; 68(1):78-86. PubMed ID: 29788296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of the DNA amplification assay for the diagnosis of C. difficile infection: a clinical comparison of fecal tests.
    Barkin JA; Nandi N; Miller N; Grace A; Barkin JS; Sussman DA
    Dig Dis Sci; 2012 Oct; 57(10):2592-9. PubMed ID: 22576711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, epidemiology and control of
    Singhal T; Shah S; Tejam R; Thakkar P
    Indian J Med Microbiol; 2018; 36(3):381-384. PubMed ID: 30429391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.